-
VITRAC Therapeutics Initiates a Phase 1 Clinical Trial with the Aurora Kinase A Inhibitor VIC-1911 and G12C Inhibitor Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer
24 Jan 2023 18:44 GMT
… treatment of KRAS G12C-mutant non-small cell lung cancer (NSCLC). … demonstrated monotherapy activity in KRAS G12C-mutant human … potential therapeutic approach for KRAS G12C-mutant patients with … their respective monotherapies in KRAS G12C-mutant NSCLC xenograft …
-
Will ThermoFisher’s ‘NGS for diagnosing only lung cancer’ do its job?
06 Jan 2023 09:51 GMT
… ERBB3, FGFR2, FGFR3, HRAS, KIT, KRAS, MAP2K1, MAP2K2, MET, MTOR, NRAS … to ThermoFisher Scientific.
Accordingly, Korean lung cancer specialists have long waited to … analysis system only for lung cancer treatment,” a lung cancer specialist said.
The specialist …
-
Innovent Announces NMPA's Breakthrough Therapy Designation for IBI351 (KRAS G12C Inhibitor) as Monotherapy for Previous Treated Advanced Non-small Cell Lung Cancer
05 Jan 2023 04:04 GMT
… advanced non-small cell lung cancer patients with KRASG12C … advanced non-small cell lung cancer patients with KRASG12C mutation … About Non-small Cell Lung Cancer
Lung cancer is one of the … about 85% of all lung cancers. KRAS mutations are common driver …
-
Biomea Fusion Doses First Patient in Phase I/Ib Clinical Trial (COVALENT-102) of BMF-219 in KRAS Mutant Solid Tumors
17 Jan 2023 13:00 GMT
… patients with KRAS-mutated non-small cell lung cancer (NSCLC), … address multiple activating KRAS mutations.” KRAS is the most … and PDAC. KRAS G12C, KRAS G12D and KRAS G12V are among … of lung cancer, representing approximately 82% of all lung cancer cases …
-
Sotorasib in KRAS p.G12C–Mutated Advanced Pancreatic Cancer
09 Jan 2023 22:28 GMT
… with non-small-cell lung cancer with a KRAS p.G12C mutation. … showed some efficacy against KRAS p.G12C mutated pancreatic cancer … metastatic pancreatic cancer with the KRAS p.G12C mutation. Patients … showed some efficacy against KRAS p.G12C mutated pancreatic …
-
The Path to Personalized Treatment in KRAS-Mutant Non-Small Cell Lung Cancer: A Review of Targeted Therapies and Immunotherapy
16 Dec 2022 05:17 GMT
… deactivation process of KRAS.
Abbreviations: KRAS, Kirsten rat … immunomodulatory effects of KRAS-mutant lung cancers exhibit different … advanced non–small cell lung cancer (NSCLC) harboring KRASG12C … patients with advanced lung cancer and oncogenic driver …
-
KRAZATI™ (adagrasib) Now Available from Onco360 for the Treatment of Adult Patients with KRAS G12C-mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
15 Dec 2022 22:58 GMT
… KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer … Unfortunately, 56% of lung cancer patients already have metastatic … Patients with metastatic lung cancer have a dismal … small cell lung cancer (NSCLC) harboring the KRAS G12C mutation …
-
FDA approves adagrasib for certain adults with non-small cell lung cancer
14 Dec 2022 00:55 GMT
… adults with non-small cell lung cancer. The indication applies to use … FDA also approved the therascreen KRAS RGQ PCR kit (Qiagen) and …
-
US FDA grants accelerated approval for Mirati’s lung cancer therapy
13 Dec 2022 17:21 GMT
… or metastatic non-small cell lung cancer (NSCLC) in adults.
The therapy … the historically difficult-to-treat KRAS mutation.
“We look forward to …
-
USFDA grants accelerated approval for Mirati Therapeutics lung cancer drug KRAZATI
13 Dec 2022 12:27 GMT
… or metastatic non-small cell lung cancer (NSCLC), as determined by … the historically difficult-to-treat KRAS mutation," David Meek, … KRASG12C is the most common KRAS mutation in NSCLC, patients … of the GO2 Foundation for Lung Cancer. "I'm …
About
© 1995-2023